| Theme | Controversies in the Drug Therapy of Upper Gastrointestinal Tract Disorders | |
|---|---|---|
| Title | Should H2-receptor Antagonists be the Drug of First Choice for Treatment of Acute Gastritis ? | |
| Publish Date | 1999/11 | |
| Author | Ariyoshi Iwasaki | 3rd Department of Internal Medicine, Nihon University School of Medicine |
| [ Summary ] | In a double-blind controlled trial study on the treatment of acute gastritis, along with the acute excaberation of chronic gastritis, H2-receptor antagonists were compared in relation to mucosal protective agents. With mucosal protective agents, treatment doses were the same as those for peptic ulcers, with the duration of administration being four weeks. The dosage of H2-receptor antagonists for treatment of gastritis is half that of the dosage used for peptic ulcer treatment. Duration of administration is two weeks. In one study comparing mucosal protective agents with H2-receptor antagonists, TA2711 showed a higher rate of improvement, compared to cimetidine. In conclusion, it is believed that H2-receptor antagonists may be useful as a first line of treatment for acute gastritis. |
|